In cultured intestinal myofibroblasts, Atopaxar pretreatment inhibited ERK1/2 phosphorylation in the comparison with thrombin control. Atopaxar hydrobromide added to iCell neuron media was not significantly more toxic than control media containing the same DMSO concentration. In E4+ HUVEC, Atopaxar pretreatment abolished the E-selectin expression response to TFLLR. In cultured intestinal myofibroblasts, Atopaxar prevented IL6-induced, but not basal, phosphorylation of STAT3. [1,2,3]
Literature-reported observations and conditions; not Adooq-tested protocols or general treatment recommendations.
Atopaxar inhibits thrombin-induced ERK1/2 phosphorylation
Cell-based study · cultured intestinal myofibroblasts [1]
In cultured intestinal myofibroblasts, Atopaxar pretreatment inhibited ERK1/2 phosphorylation compared with thrombin treatment alone.
Literature-Reported Treatment Conditions
- Treatment concentration
- 1 μmol/L
- Exposure duration
- thrombin for 5 minutes
- Method
- pretreatment
- Co-treatment
- Other interventions in this design: thrombin 1 U/mL. Compound effect isolated by the comparison: 1 U/mL thrombin.
- Reported limits
- Not stated in the sentences used: vehicle.
Methods and source locations
Compound reported in the paper: Atopaxar; Compound label in the paper: E5555
The paper names Atopaxar without stating the salt or form; not verified as the hydrobromide form supplied as A13813. No dose conversion or lot validation.
Results > E5555 Suppressed the Phosphorylation of ERK and STAT3 in the Cultured Intestinal Myofibroblasts (S87, S88, S91)
phosphorylation of ERK1/2: phosphorylation of ERK1/2; comparator: 1 U/mL thrombin — Results > E5555 Suppressed the Phosphorylation of ERK and STAT3 in the Cultured Intestinal Myofibroblasts (S88, S91)
Atopaxar neuronal toxicity assessment
Cell-based study · iCell neurons; n = 8 per condition [2]
In iCell neurons, Atopaxar hydrobromide was placed into the media. Treatment was not significantly more toxic than control media containing the same concentration of DMSO.
Literature-Reported Treatment Conditions
- Method
- placed into the media
- Vehicle
- DMSO
- Reported limits
- Not stated in the sentences used: dose, schedule.
Methods and source locations
Compound reported in the paper: Atopaxar hydrobromide; Compound label in the paper: Atopaxar
Literature evidence for the named compound in the stated model; no Adooq product-use or lot-performance claim.
Methods > Neuronal cultures (S6); Results > PAR1 activation mediates granzyme B neurotoxicity (S144); Fig. 6 legend (S194)
toxicity: toxicity; comparator: control media, which contained the same concentration of DMSO necessary to solubilize Atopaxar — Fig. 6 legend (S194)
Atopaxar and endothelial E-selectin expression
Cell-based study · E4+ HUVEC [3]
In E4+ HUVEC, Atopaxar pretreatment abolished the E-selectin expression response to the agonist peptide TFLLR.
Literature-Reported Treatment Conditions
- Treatment concentration
- 0.1 μM
- Exposure duration
- for 30 min at 37°C
- Method
- Pretreatment of endothelial cells
- Co-treatment
- Other interventions in this design: TFLLR 100 μM; amastatin 10 μM. Compound effect isolated by the comparison: PAR-1 agonist peptide, TFLLR.
- Reported limits
- Not stated in the sentences used: vehicle.
Methods and source locations
Compound reported in the paper: Atopaxar; Compound label in the paper: E5555
The paper names Atopaxar without stating the salt or form; not verified as the hydrobromide form supplied as A13813. No dose conversion or lot validation.
Materials and Methods > Exposure of Endothelial Cells to EV (S26, S27); Results > TF-Expressing Tumor-Derived EV Upregulate Endothelial E-Selectin Expression and Induce IL-8 Secretion in a TF-, FXa-, and PAR-1-Dependent, but PAR-2-Independent, Manner (S80, S82); Figure 5 legend (S117, S119)
E-selectin expression: E-selectin expression; comparator: PAR-1 agonist peptide, TFLLR — Results > TF-Expressing Tumor-Derived EV Upregulate Endothelial E-Selectin Expression and Induce IL-8 Secretion in a TF-, FXa-, and PAR-1-Dependent, but PAR-2-Independent, Manner (S82); Figure 5 legend (S119)
Atopaxar prevents IL6-induced STAT3 phosphorylation
Cell-based study · cultured intestinal myofibroblasts [1]
In cultured intestinal myofibroblasts, Atopaxar prevented IL6-induced STAT3 phosphorylation compared with IL6 treatment alone, while basal STAT3 phosphorylation was unaffected.
Literature-Reported Treatment Conditions
- Treatment concentration
- 1 μmol/L
- Co-treatment
- Other interventions in this design: IL6 5 ng/mL. Compound effect isolated by the comparison: 5 ng/mL IL6.
- Reported limits
- Not stated in the sentences used: route, schedule, vehicle.
Methods and source locations
Compound reported in the paper: Atopaxar; Compound label in the paper: E5555
The paper names Atopaxar without stating the salt or form; not verified as the hydrobromide form supplied as A13813. No dose conversion or lot validation.
Results > E5555 Suppressed the Phosphorylation of ERK and STAT3 in the Cultured Intestinal Myofibroblasts (S90, S93)
phosphorylation of STAT3: phosphorylation of STAT3; comparator: 5 ng/mL IL6 — Results > E5555 Suppressed the Phosphorylation of ERK and STAT3 in the Cultured Intestinal Myofibroblasts (S90, S93)